Cardiac sarcoidosis-state of the art review

Cardiovascular Diagnosis and Therapy

Volumn 6, Issue 1, 2016, Pages 50-63

  Hulten, Edward ^a,b   Aslam, Saira ^a   Osborne, Michael ^c   Abbasi, Siddique ^b   Bittencourt, Marcio Sommer ^d,e   Blankstein, Ron ^b  

^a WALTER REED ARMY MEDICAL CENTER   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c MASSACHUSETTS GENERAL HOSPITAL   (United States)

^d UNIVERSITY OF SÃO PAULO   (Brazil)

^e HOSPITAL ISRAELITA ALBERT EINSTEIN   (Brazil)

Author keywords

Cardiac MRI; Cardiac positron emission tomography (cardiac PET); Cardiac sarcoidosis; Review

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; FLUORODEOXYGLUCOSE F 18; GALLIUM 67; METHOTREXATE; PREDNISONE; TECHNETIUM 99M; THALLIUM 201;

CARDIAC IMAGING; CARDIOVASCULAR MAGNETIC RESONANCE; DEVICE THERAPY; DIAGNOSTIC TEST; DIAGNOSTIC VALUE; ECHOCARDIOGRAPHY; EVIDENCE BASED MEDICINE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART VENTRICLE TACHYCARDIA; HIGH RISK PATIENT; HUMAN; IMPLANTABLE CARDIOVERTER DEFIBRILLATOR; MYOCARDITIS; PACEMAKER; POSITRON EMISSION TOMOGRAPHY; PREVALENCE; PROGNOSIS; REVIEW; SARCOIDOSIS;

EID: 84971557424     PISSN: 22233652     EISSN: 22233660     Source Type: Journal    
DOI: 10.3978/j.issn.2223-3652.2015.12.13     Document Type: Review

References (60)

1. James DG, Sharma OP. From Hutchinson to now: A historical glimpse. Curr Opin Pulm Med 2002;8:416-23.
2. Valeyre D, Prasse A, Nunes H, et al. Sarcoidosis. Lancet 2014;383:1155-67.
3. Ardehali H, Howard DL, Hariri A, et al. A positive endomyocardial biopsy result for sarcoid is associated with poor prognosis in patients with initially unexplained cardiomyopathy. Am Heart J 2005;150:459-63.
4. Rybicki BA, Major M, Popovich J Jr, et al. Racial differences in sarcoidosis incidence: A 5-year study in a health maintenance organization. Am J Epidemiol 1997;145:234-41.
5. Iwai K, Takemura T, Kitaichi M, et al. Pathological studies on sarcoidosis autopsy. II. Early change, mode of progression and death pattern. Acta Pathol Jpn 1993;43:377-85.
6. Guideline for Diagnosis of Cardiac Sarcoidosis: Study Report on Diffuse Pulmonary Diseases. Tokyo Japan: Ministry of Health, Labour and Welfare, 1993:23-4.
7. Birnie DH, Sauer WH, Bogun F, et al. HRS expert consensus statement on the diagnosis and management of arrhythmias associated with cardiac sarcoidosis. Heart Rhythm 2014;11:1305-23.
8. Ohira H, Tsujino I, Ishimaru S, et al. Myocardial imaging with 18F-fluoro-2-deoxyglucose positron emission tomography and magnetic resonance imaging in sarcoidosis. Eur J Nucl Med Mol Imaging 2008;35:933-41.
9. Nery PB, Beanlands RS, Nair GM, et al. Atrioventricular block as the initial manifestation of cardiac sarcoidosis in middle-Aged adults. J Cardiovasc Electrophysiol 2014;25:875-81.
10. Yazaki Y, Isobe M, Hiroe M, et al. Prognostic determinants of long-Term survival in Japanese patients with cardiac sarcoidosis treated with prednisone. Am J Cardiol 2001;88:1006-10.
11. Patel MR, Cawley PJ, Heitner JF, et al. Detection of myocardial damage in patients with sarcoidosis. Circulation 2009;120:1969-77.
12. Blankstein R, Osborne M, Naya M, et al. Cardiac positron emission tomography enhances prognostic assessments of patients with suspected cardiac sarcoidosis. J Am Coll Cardiol 2014;63:329-36.
13. Greulich S, Deluigi CC, Gloekler S, et al. CMR imaging predicts death and other adverse events in suspected cardiac sarcoidosis. JACC Cardiovasc Imaging 2013;6:501-11.
14. Tahara N, Tahara A, Nitta Y, et al. Heterogeneous myocardial FDG uptake and the disease activity in cardiac sarcoidosis. JACC Cardiovasc Imaging 2010;3:1219-28.
15. Kim JS, Judson MA, Donnino R, et al. Cardiac sarcoidosis. Am Heart J 2009;157:9-21.
16. Vorselaars AD, Cremers JP, Grutters JC, et al. Cytotoxic agents in sarcoidosis: which one should we choose? Curr Opin Pulm Med 2014;20:479-87.
17. Osborne M, Kolli S, Padera R, et al. Use of multimodality imaging to diagnose cardiac sarcoidosis as well as identify recurrence following heart transplantation. J Nucl Cardiol 2013;20:310-2.
18. Osborne MT, Hulten EA, Singh A, et al. Reduction in 18F-fluorodeoxyglucose uptake on serial cardiac positron emission tomography is associated with improved left ventricular ejection fraction in patients with cardiac sarcoidosis. J Nucl Cardiol 2014;21:166-74.
19. Nagai S, Yokomatsu T, Tanizawa K, et al. Treatment with methotrexate and low-dose corticosteroids in sarcoidosis patients with cardiac lesions. Intern Med 2014;53:427-33.
20. Hunt SA; American College of Cardiology; American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure). ACC/AHA 2005 guideline update for the diagnosis and management of chronic heart failure in the adult: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure). J Am Coll Cardiol 2005;46:e1-82.
21. Epstein AE, DiMarco JP, Ellenbogen KA, et al. 2012 ACCF/AHA/HRS focused update incorporated into the ACCF/AHA/HRS 2008 guidelines for device-based therapy of cardiac rhythm abnormalities: A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. J Am Coll Cardiol 2013;61:e6-75.
22. Soejima K, Yada H. The work-up and management of patients with apparent or subclinical cardiac sarcoidosis: with emphasis on the associated heart rhythm abnormalities. J Cardiovasc Electrophysiol 2009;20:578-83.
23. Diagnostic standard and guidelines for sarcoidosis. Jpn J Sarcoidosis Granulomatous Disord 2007;27:89-102.
24. Mc Ardle BA, Leung E, Ohira H, et al. The role of F(18)-fluorodeoxyglucose positron emission tomography in guiding diagnosis and management in patients with known or suspected cardiac sarcoidosis. J Nucl Cardiol 2013;20:297-306.
25. Okayama K, Kurata C, Tawarahara K, et al. Diagnostic and prognostic value of myocardial scintigraphy with thallium-201 and gallium-67 in cardiac sarcoidosis. Chest 1995;107:330-4.
26. Yamagishi H, Shirai N, Takagi M, et al. Identification of cardiac sarcoidosis with (13)N-NH(3)/(18)F-FDG PET. J Nucl Med 2003;44:1030-6.
27. Ohira H, Tsujino I, Yoshinaga K. 18F-Fluoro-2-deoxyglucose positron emission tomography in cardiac sarcoidosis. Eur J Nucl Med Mol Imaging 2011;38:1773-83.
28. Youssef G, Leung E, Mylonas I, et al. The use of 18F-FDG PET in the diagnosis of cardiac sarcoidosis: A systematic review and metaanalysis including the Ontario experience. J Nucl Med 2012;53:241-8.
29. Smedema JP, Snoep G, van Kroonenburgh MP, et al. Evaluation of the accuracy of gadolinium-enhanced cardiovascular magnetic resonance in the diagnosis of cardiac sarcoidosis. J Am Coll Cardiol 2005;45:1683-90.
30. Judson MA, Baughman RP, Teirstein AS, et al. Defining organ involvement in sarcoidosis: The ACCESS proposed instrument. ACCESS Research Group. A Case Control Etiologic Study of Sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 1999;16:75-86.
31. Judson MA, Costabel U, Drent M, et al. The WASOG Sarcoidosis Organ Assessment Instrument: An update of a previous clinical tool. Sarcoidosis Vasc Diffuse Lung Dis 2014;31:19-27.
32. Hamzeh NY, Wamboldt FS, Weinberger HD. Management of cardiac sarcoidosis in the United States: A Delphi study. Chest 2012;141:154-62.
33. Burstow DJ, Tajik AJ, Bailey KR, et al. Two-dimensional echocardiographic findings in systemic sarcoidosis. Am J Cardiol 1989;63:478-82.
34. Smedema JP. Tissue Doppler imaging in cardiac sarcoidosis. Eur J Echocardiogr 2008;9:579-80.
35. Patel AR, Klein MR, Chandra S, et al. Myocardial damage in patients with sarcoidosis and preserved left ventricular systolic function: An observational study. Eur J Heart Fail 2011;13:1231-7.
36. Dubrey SW, Falk RH. Diagnosis and management of cardiac sarcoidosis. Prog Cardiovasc Dis 2010;52:336-46.
37. Bruder O, Schneider S, Pilz G, et al. 2015 Update on Acute Adverse Reactions to Gadolinium based Contrast Agents in Cardiovascular MR. Large Multi-National and Multi-Ethnical Population Experience With 37788 Patients From the EuroCMR Registry. J Cardiovasc Magn Reson 2015;17:58.
38. Beckett KR, Moriarity AK, Langer JM. Safe Use of Contrast Media: What the Radiologist Needs to Know. Radiographics 2015;35:1738-50.
39. McDonald RJ, McDonald JS, Kallmes DF, et al. Intracranial Gadolinium Deposition after Contrastenhanced MR Imaging. Radiology 2015;275:772-82.
40. Shimada T, Shimada K, Sakane T, et al. Diagnosis of cardiac sarcoidosis and evaluation of the effects of steroid therapy by gadolinium-DTPA-enhanced magnetic resonance imaging. Am J Med 2001;110:520-7.
41. Schulz-Menger J, Wassmuth R, Abdel-Aty H, et al. Patterns of myocardial inflammation and scarring in sarcoidosis as assessed by cardiovascular magnetic resonance. Heart 2006;92:399-400.
42. Crouser ED, Ono C, Tran T, et al. Improved Detection of Cardiac Sarcoidosis Using Magnetic Resonance with Myocardial T2 Mapping. Am J Respir Crit Care Med 2014;189:109-12.
43. Roberts WC, McAllister Jr HA, Ferrans VJ. Sarcoidosis of the heart: A clinicopathologic study of 35 necropsy patients (group I) and review of 78 previously described necropsy patients (group II). Am J Med 1977;63:86-108.
44. Parsai C, OHanlon R, Prasad SK, et al. Diagnostic and prognostic value of cardiovascular magnetic resonance in non-ischaemic cardiomyopathies. J Cardiovasc Magn Reson 2012;14:54.
45. Dilsizian V, Bacharach SL, Beanlands RS, et al. ASNC imaging guidelines for nuclear cardiology procedures: PET myocardial perfusion and metabolism clinical imaging. J Nucl Cardiol 2009;16:651.
46. Holly TA, Abbott BG, Al-Mallah M, et al. Single photon-emission computed tomography. J Nucl Cardiol 2010;17:941-73.
47. Gotthardt M, Bleeker-Rovers CP, Boerman OC, et al. Imaging of inflammation by PET, conventional scintigraphy, and other imaging techniques. J Nucl Med 2010;51:1937-49.
48. Nishiyama Y, Yamamoto Y, Fukunaga K, et al. Comparative evaluation of 18F-FDG PET and 67Ga scintigraphy in patients with sarcoidosis. J Nucl Med 2006;47:1571-6.
49. Mehta D, Lubitz SA, Frankel Z, et al. Cardiac involvement in patients with sarcoidosis: diagnostic and prognostic value of outpatient testing. Chest 2008;133:1426-35.
50. Skali H, Schulman AR, Dorbala S. 18F-FDG PET/CT for the assessment of myocardial sarcoidosis. Curr Cardiol Rep 2013;15:352.
51. Morooka M, Moroi M, Uno K, et al. Long fasting is effective in inhibiting physiological myocardial 18 F-FDG uptake and for evaluating active lesions of cardiac sarcoidosis. EJNMMI Res 2014;4:1.
52. Okumura W, Iwasaki T, Toyama T, et al. Usefulness of fasting 18F-FDG PET in identification of cardiac sarcoidosis. J Nucl Med 2004;45:1989-98.
53. Ishimaru S, Tsujino I, Takei T, et al. Focal uptake on 18F-fluoro-2-deoxyglucose positron emission tomography images indicates cardiac involvement of sarcoidosis. Eur Heart J 2005;26:1538-43.
54. Langah R, Spicer K, Gebregziabher M, et al. Effectiveness of prolonged fasting 18f-FDG PET-CT in the detection of cardiac sarcoidosis. J Nucl Cardiol 2009;16:801-10.
55. Betensky BP, Tschabrunn CM, Zado ES, et al. Longterm follow-up of patients with cardiac sarcoidosis and implantable cardioverter-defibrillators. Heart Rhythm 2012;9:884-91.
56. Ahmadian A, Brogan A, Berman J, et al. Quantitative interpretation of FDG PET/CT with myocardial perfusion imaging increases diagnostic information in the evaluation of cardiac sarcoidosis. J Nucl Cardiol 2014;21:925-39.
57. Dweck MR, Jones C, Joshi NV, et al. Assessment of valvular calcification and inflammation by positron emission tomography in patients with aortic stenosis. Circulation 2012;125:76-86.
58. Chiu CZ, Nakatani S, Zhang G, et al. Prevention of left ventricular remodeling by long-Term corticosteroid therapy in patients with cardiac sarcoidosis. Am J Cardiol 2005;95:143-6.
59. Grutters JC, van Den Bosch JM. Corticosteroid treatment in sarcoidosis. Eur Respir J 2006;28:627-36.
60. Nekolla SG, Martinez-Moeller A, Saraste A. PET and MRI in cardiac imaging: from validation studies to integrated applications. Eur J Nucl Med Mol Imaging 2009;36 Suppl 1:S121-30.